Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Of...
30 November 2017 - 10:00PM
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company
focused on improving patients’ lives by identifying, developing,
acquiring and commercializing differentiated medicines that address
unmet medical needs, today named Shao-Lee Lin, M.D., Ph.D.,
executive vice president, research and development and chief
scientific officer reporting directly to Timothy P. Walbert,
chairman, president and chief executive officer. Dr. Lin will
join Horizon in early January 2018.
“Shao-Lee has exceptional experience and a proven track record
of developing new medicines and shares Horizon’s focus on improving
patient outcomes,” said Walbert. “As we accelerate the
development of a robust research and development portfolio of
medicines, we have a new leader to drive the next phase of growth
for Horizon.”
Dr. Lin is an accomplished pharmaceutical executive, physician
and scientist with more than 20 years of academic and clinical
research experience. Prior to Horizon, Dr. Lin was a
corporate officer and vice president, therapeutic areas,
development excellence and international development at
AbbVie. In that role, she led immunology, virology,
neuroscience and general medicine, across on-market and pipeline
compounds as well as international development across all
therapeutic areas.
“I’ve committed my career to developing medicines that have a
meaningful impact on patients’ lives,” said Dr. Lin. “I’m
impressed by Horizon’s rapid growth and its strategy for evolution
from primary care, with a focus on marketed medicines, to
diversifying into rare diseases and rheumatology and now committed
to the next stage in its transformation of building a robust and
sustainable research and development portfolio.”
Prior to AbbVie, Dr. Lin was vice president, inflammation and
respiratory development at Gilead. She also held leadership
positions in immunology and other therapeutic areas while at
Amgen.
Dr. Lin received her medical degree and doctorate at the Johns
Hopkins University School of Medicine and completed fellowships and
post-doctoral work in rheumatology, allergy and immunology at the
University of California San Diego and The Scripps Clinic and
Research Institute. She received a Bachelor of Science in
biochemistry and chemical engineering from Rice University.
Dr. Lin has also been faculty as a Clinical Scholar at the
Rockefeller University, and adjunct faculty at Cornell, UCLA,
Stanford and Northwestern medical schools.
About Horizon Pharma plcHorizon Pharma
plc is a biopharmaceutical company focused on improving
patients' lives by identifying, developing, acquiring and
commercializing differentiated and accessible medicines that
address unmet medical needs. The Company markets 11 medicines
through its orphan, rheumatology and primary care business units.
For more information, please
visit www.horizonpharma.com.
Follow @HZNPplc on Twitter, like us on Facebook or view
careers on our LinkedIn page.
Contacts:Tina VenturaSenior Vice President,
Investor RelationsInvestor-relations@horizonpharma.com
Ruth VenningExecutive Director, Investor
RelationsInvestor-relations@horizonpharma.com
U.S. Media Contact:Geoffrey CurtisSenior Vice President,
Corporate Affairs and Chief Communications
Officermedia@horizonpharma.com
Ireland Media Contact: Ray Gordon Gordon MRM
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024